angle-double-leftangle-double-rightcancelchevron-downchevron-upcirclecircle-oclose-xangle-double-rightFacebookglobegoogleplusleft-openlinkedinmailmenuminusplusplus-circleplus-circle-outlinepopuprefreshright-opensearchsearch-plussort-downthin-leftthin-righttimes-circletwitter

Explore Investigational Agents

Phase 1

Avadomide (CC-122)

( Cereblon Targeting Agent )

LEARN MORE
Phase 1

Avadomide (CC-122)

( Cereblon Targeting Agent )

Avadomide (CC-122) is a non-phthalimide analogue and pleiotropic pathway modifier.

LEARN MORE

Phase 2

bb2121a

( Anti-BCMA CAR T Cells )

LEARN MORE
Phase 2

bb2121a

( Anti-BCMA CAR T Cells )

bb2121 is an investigational chimeric antigen receptor (CAR) T cell therapy targeting B-cell maturation agent.

a In collaboration with bluebird bio, Inc.

LEARN MORE

CC-486

( DNA Methyltransferase Inhibitor )

LEARN MORE

CC-486

( DNA Methyltransferase Inhibitor )

The epigenetic modifier CC-486 (an oral formulation of azacitidine) is a cytidine nucleoside analogue.

LEARN MORE

Phase 1

CC-90002

( Anti-CD47 Antibody )

LEARN MORE
Phase 1

CC-90002

( Anti-CD47 Antibody )

CC-90002 is an anti-CD47 antibody. CD47 interacts with signal regulatory protein-α (SIRPα) on macrophages to inhibit cell phagocytosis.

LEARN MORE

Enasidenib

( IDH2 Inhibitor )

LEARN MORE

Enasidenib

( IDH2 Inhibitor )

Enasidenib is an oral, reversible, selective inhibitor of mutated isocitrate dehydrogenase (IDH) 2.

LEARN MORE

Lenalidomide

( IMiD® Agent )

LEARN MORE

Lenalidomide

( IMiD® Agent )

Lenalidomide is an oral, small-molecule immunomodulatory agent.

LEARN MORE

Phase 1

Lisocabtagene maraleucel

( Anti-CD19 CAR T Cells )

LEARN MORE
Phase 1

Lisocabtagene maraleucel

( Anti-CD19 CAR T Cells )

Lisocabtagene maraleucel (liso-cel;JCAR017) is an investigational chimeric antigen receptor (CAR) T cell therapy designed to target CD19.

LEARN MORE

Luspatercepta

( Erythroid Maturation Agent )

LEARN MORE

Luspatercepta

( Erythroid Maturation Agent )

Luspatercept (ACE-536) is a soluble fusion protein hypothesized to act as an erythroid maturation agent.

a In collaboration with Acceleron Pharma Inc.

LEARN MORE

Phase 2

Marizomib

( Proteasome Inhibitor )

LEARN MORE
Phase 2

Marizomib

( Proteasome Inhibitor )

Marizomib is a proteasome inhibitor derived from a novel marine-obligate actinomycete.

LEARN MORE

nab-Paclitaxel

( Albumin-Bound Microtubule Inhibitor )

LEARN MORE

nab-Paclitaxel

( Albumin-Bound Microtubule Inhibitor )

nab-Paclitaxel is a taxane that uses albumin to deliver paclitaxel.

LEARN MORE

Post Approval Research

Pomalidomide

( IMiD® Agent )

LEARN MORE
Post Approval Research

Pomalidomide

( IMiD® Agent )

Pomalidomide is an oral immunomodulatory agent.

LEARN MORE

Phase 3

Tislelizumab (BGB-A317)a

( Anti–PD-1 Monoclonal Antibody )

LEARN MORE
Phase 3

Tislelizumab (BGB-A317)a

( Anti–PD-1 Monoclonal Antibody )

Tislelizumab is a monoclonal antibody against programmed cell death protein 1 (PD-1).

a In collaboration with BeiGene, Ltd.

LEARN MORE

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

You are now leaving www.RESEARCHONCOLOGY.com, a website provided by Celgene. This link will take you to a website to which this Privacy Policy does not apply. We encourage you to read the Privacy Policy of every website you visit. Celgene does not endorse and/or influence the content found on websites not owned/operated by Celgene.